Systemic sclerosis & Raynaud's
Cumulative disease damage and anti-PM/Scl antibodies are associated with a heavy burden of calcinosis in systemic sclerosis
Authors' conclusion
Calcinosis burden is associated with cumulative SSc-related tissue damage. Independent of disease severity, autoantibodies to PM/Scl are also associated with a heavy burden of calcinosis.
Study context
- Population
- Patients in the Johns Hopkins Scleroderma Center Research Registry with SSc997 with calcinosis
- Participants
- 3,388 patients
- Exposure
- Latent phenotypic classes and autoantibodies as risk factors for heavy vs light vs no calcinosis
- Outcome
- Calcinosis burden (heavy, light or none) by pre-specified definitions
Methodological detailsregistry-based, latent class analysis, multinomial logistic regression
- Registry-based
- Latent class analysis
- Multinomial logistic regression
Main finding
As reported in the abstract
Heavy burden of calcinosis
Odds ratio (95% CI)P value
Diffuse/severe classvs Limited class
6.92(3.66–13.08)
P < 0.001Anti-PM/Scl
17.31(7.72–38.81)
P < 0.001Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Light burden of calcinosisDiffuse/severe classvs Limited class | 2.88 (2.11–3.95) | P < 0.001 | |
| 0.20.5125Odds ratio (log scale) |
Light burden of calcinosis
| OR (95% CI) | P value | ||
|---|---|---|---|
| Anti-PM/Scl | 3.59 (1.84–7.00) | P < 0.001 | |
| 0.10.31310Odds ratio (log scale) |
Prevalence of calcinosis; heavy burden among those with calcinosis
- Calcinosis, all patients
- 29.4% (997/3388)
- Heavy burden among those with calcinosis
- 13.5% (130/963)
Original publication
Cumulative disease damage and anti-PM/Scl antibodies are associated with a heavy burden of calcinosis in systemic sclerosis. Rheumatology (Oxford). Published 5 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →